查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1628055

抗體藥物偶聯物 (ADC) 2025-2035

Antibody Drug Conjugates Market Report 2025-2035
出版日期: | 出版商: Visiongain | 英文 342 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2035 年全球抗體藥物偶聯物 (ADC) 市場將以 14.9% 的複合年增長率成長。

抗體-藥物偶聯物（ADC）的興起

抗體-藥物偶聯物 (ADC) 將標靶治療的精確性與細胞毒藥物的療效相結合，徹底改變了癌症治療。這種創新療法將強效有效載荷（包括 DNA 損傷劑和微管抑制劑）直接輸送到癌細胞，從而減少脫靶效應和全身毒性。這項進步擴大了 ADC 的用途，從治療血液系統惡性腫瘤擴展到實體腫瘤，治療卵巢癌和肺癌等複雜惡性腫瘤。

此外，截至 2023 年，已有超過 90 種 ADC 候選藥物進入臨床試驗，顯示其研發管線強勁且前景廣闊。雙特異性 ADC 和聯合療法等突破正在為更高的成功率和擴大應用鋪平道路。新創公司和老牌製藥公司正在共同努力，進一步突破這些界限，AstraZeneca、Daiichi Sankyo等公司都取得了全球里程碑。

抗體藥物偶聯物（ADC）的出現代表了精準癌症治療發展的一個重要里程碑。透過針對特定的癌症抗原並精確地遞送有效載荷，ADC 可以提高治療效果並減少副作用。生物標記辨識等分子診斷技術的進步提高了診斷的精確度，使得可以根據患者的個人化需求制定治療方案。

本報告研究了全球抗體藥物偶聯物 (ADC) 市場，提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測以及各個細分市場、地區/主要國家的市場佔有率。其中包括詳細的分析、競爭格局和關鍵公司簡介。

目錄

第1章 報告概述

第 2 章執行摘要

第3章 市場概況

  • 主要發現
  • 市場動態
  • 影響分析
    • 市場驅動力
    • 市場阻礙因素
    • 市場機會
  • SWOT分析
  • 監管框架
  • 波特五力分析
  • PEST分析
  • 抗體偶聯藥物（ADC）的研發現況及臨床進展
  • ADC 醫療行動的關鍵考量因素
  • 商業課題
  • 製藥公司期待第二波 ADC 上市
  • 已核准的 ADC

第4章體藥物偶聯物 (ADC) 市場以有效載荷類型進行分析

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • MMAE
  • DM4
  • 喜樹鹼
  • DM1
  • MMAF
  • 其他
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第5章抗體藥物偶聯物 (ADC) 市場按連接子類型進行分析

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 可裂解接頭
  • 不可裂解接頭
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第6章抗體藥物偶聯物 (ADC) 市場分析（以目標抗原）

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • CD30
  • HER2
  • CD22
  • CD33
  • 其他
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第7章抗體藥物偶聯物 (ADC) 市場應用分析

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 血癌
  • 乳癌
  • 卵巢癌
  • 肺癌
  • 其他
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第8章抗體藥物偶聯物 (ADC) 市場區域分析

  • 主要發現
  • 市場規模趨勢和預測

第9章北美抗體藥物偶聯物 (ADC) 市場分析

第10章歐洲抗體藥物偶聯物 (ADC) 市場分析

第11章亞太地區抗體藥物偶聯物 (ADC) 市場分析

第12章拉丁美洲抗體藥物偶聯物 (ADC) 市場分析

第13章中東和非洲抗體藥物偶聯物 (ADC) 市場分析

第14章 公司簡介

  • 競爭環境
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • AstraZeneca
  • Gilead Sciences, Inc.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • GSK plc
  • ADC Therapeutics SA
  • Synaffix BV（now a part of Lonza）
  • Byondis
  • AbbVie Inc.
  • RemeGen
  • Oxford BioTherapeutics
  • Mersana Therapeutics
  • WuXi AppTec
  • Genmab A/S
  • Regeneron Pharmaceuticals Inc.

第 15 章概述與建議

  • Visiongain 的一般討論
  • 對參與企業的建議
Product Code: PHA1365

The global Antibody Drug Conjugates market is projected to grow at a CAGR of 14.9% by 2035.

The Antibody Drug Conjugates Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise of Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) are revolutionizing cancer therapy by merging the precision of targeted treatment with the potency of cytotoxic agents. These innovative therapies deliver powerful payloads, such as DNA-damaging agents or microtubule inhibitors, directly to cancer cells, reducing off-target effects and systemic toxicity. This advancement has allowed ADCs to expand their efficacy from treating haematological cancers to solid tumours, addressing complex malignancies like ovarian and lung cancers.

Additionally, over 90 ADC candidates in clinical trials, as of 2023, signal a robust and promising pipeline. Breakthroughs such as bispecific ADCs and combination therapies are paving the way for higher success rates and expanded applications. Startups and established pharmaceutical players are collaborating to push these boundaries further, with companies like AstraZeneca and Daiichi Sankyo achieving global milestones.

For instance, on 19th October 2023, Daiichi Sankyo and Merck entered a global agreement to jointly develop and potentially commercialize three of Daiichi Sankyo's DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). This collaboration will cover worldwide development and commercialization, excluding Japan, where Daiichi Sankyo will retain exclusive rights. Additionally, Daiichi Sankyo will handle all manufacturing and supply operations. While production challenges and cost concerns remain, the future of ADCs appears bright, driven by continuous innovation and strategic investments.

Antibody-Drug Conjugates: Pioneering the Future of Precision Cancer Therapy

The advent of Antibody-Drug Conjugates (ADCs) marks a significant milestone in the evolution of precision cancer treatment. By targeting specific cancer antigens and delivering payloads with pinpoint accuracy, ADCs are reducing side effects while enhancing therapeutic outcomes. This precision has been amplified by advancements in molecular diagnostics, such as biomarker identification, enabling treatments to be tailored to individual patient needs.

However, the journey is not without hurdle, the ADC production demands specialized technologies and facilities, driving up costs and complicating reimbursement structures. For instance, disparities in coverage policies, even in developed regions like the UK, hinder patient access to these life-saving therapies. Yet, emerging economies like China and India show potential for growth as healthcare infrastructures evolve. Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others are making strides to lower production costs and increase access. By fostering global collaborations and embracing innovation, ADCs are set to define the future of cancer therapy.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the antibody drug conjugates market evolving?
  • What is driving and restraining the antibody drug conjugates market?
  • How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each antibody drug conjugates submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the antibody drug conjugates projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2035? What are the implications of
  • antibody drug conjugates projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
  • Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:

  • Our 342-page report provides 126 tables, 185 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Payload Type
  • MMAE
  • DM4
  • Camptothecin
  • DM1
  • MMAF
  • Other Payload Type
  • Linker Type
  • Cleavable Linkers
  • Non-Cleavable Linkers
  • Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Other Target Antigens
  • Applications
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Other Applications

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South-East Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Antibody Drug Conjugates Market, 2025 to 2035, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • AstraZeneca
  • Gilead Sciences, Inc.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • GSK plc
  • ADC Therapeutics SA
  • Synaffix BV
  • Byondis
  • AbbVie Inc.
  • RemeGen
  • Oxford BioTherapeutics
  • Mersana Therapeutics
  • WuXi AppTec
  • Genmab A/S
  • Regeneron Pharmaceuticals Inc.

Overall world revenue for Antibody Drug Conjugates Market, 2025 to 2035 in terms of value the market will surpass US$16.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Antibody Drug Conjugates Market, 2025 to 2035 report help you?
  • In summary, our 340+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Antibody Drug Conjugates Market 2025 to 2035, with forecasts for Payload Type, Linker Type, Target Antigen, and Applications, each forecast at a global and regional level discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 21 key national markets See forecasts for the Antibody Drug Conjugates Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market including company profiles for 18 of the major companies involved in the Antibody Drug Conjugates Market, 2025 to 2035.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
  • Information found nowhere else
  • With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market 2025 to 2035, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Antibody Drug Conjugates Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Growing Burden of Cancer
      • 3.3.1.2 Increasing Breast Cancer Cases Driving Demand for Antibody-Drug Conjugates
      • 3.3.1.3 Presence of Strong Emerging Pipeline Drugs
      • 3.3.1.4 Increasing R&D Activities for the Development of Novel Therapeutics
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Complexities in Manufacturing
      • 3.3.2.2 Co-ordination Between Various Biopharmaceutical and CDMOs
      • 3.3.2.3 Antibody and Linker-Related Cytotoxin and Formulation Challenges
      • 3.3.2.4 Adverse Effects of Antibody-Drug Conjugates
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Adoption of Combination Therapies
      • 3.3.3.2 Advancements in Antibody-Drug Conjugates (ADCs)
      • 3.3.3.3 Expanding Industry Investments and Collaborations in ADC Development
  • 3.4 SWOT Analysis
  • 3.5 Regulatory Framework
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Suppliers
    • 3.6.2 Bargaining Power of Buyers
    • 3.6.3 Competitive Rivalry
    • 3.6.4 Threat of Substitutes
    • 3.6.5 Threat of New Entrants
  • 3.7 PEST
    • 3.7.1 Political
    • 3.7.2 Economical
    • 3.7.3 Social
    • 3.7.4 Technological
  • 3.8 Current R&D and Clinical Status of Antibody Drug Conjugates
    • 3.8.1 Antibody Drug Considerations
    • 3.8.2 Drug to Antibody Ration (DAR)
    • 3.8.3 Bystander Effect and Linker Design
    • 3.8.4 Future Clinical Differentiation
  • 3.9 Key Medical Affairs Considerations for ADCs
    • 3.9.1 Precision in Indication and Timing
    • 3.9.2 Combination Partners and Customisation
    • 3.9.3 Balancing Dose and Toxicity
    • 3.9.4 Patient-Centred Decision Making
  • 3.10 Commercial Challenges
    • 3.10.1 Physician Variability and Market Variability
    • 3.10.2 Reposition Value Narratives
    • 3.10.3 Reimbursement and Cost Considerations
  • 3.11 Pharma is Expecting a Second Wave of ADC Launches
  • 3.12 Approved ADCs

4 Antibody Drug Conjugates Market Analysis by Payload Type

  • 4.1 Key Findings
  • 4.2 Payload Type Segment: Market Attractiveness Index
  • 4.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 4.4 MMAE
    • 4.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 DM4
    • 4.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)
  • 4.6 Camptothecin
    • 4.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.6.2 Market Share by Region, 2025 & 2035 (%)
  • 4.7 DM1
    • 4.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.7.2 Market Share by Region, 2025 & 2035 (%)
  • 4.8 MMAF
    • 4.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.8.2 Market Share by Region, 2025 & 2035 (%)
  • 4.9 Other Payload Type
    • 4.9.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 4.9.2 Market Share by Region, 2025 & 2035 (%)

5 Antibody Drug Conjugates Market Analysis by Linker Type

  • 5.1 Key Findings
  • 5.2 Linker Type Segment: Market Attractiveness Index
  • 5.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 5.4 Cleavable Linkers
    • 5.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 5.4.2 Market Share by Region, 2025 & 2035 (%)
  • 5.5 Non-Cleavable Linkers
    • 5.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Antibody Drug Conjugates Market Analysis by Target Antigen

  • 6.1 Key Findings
  • 6.2 Target Antigen Segment: Market Attractiveness Index
  • 6.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 6.4 CD30
    • 6.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 6.4.2 Market Share by Region, 2025 & 2035 (%)
  • 6.5 HER2
    • 6.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 6.5.2 Market Share by Region, 2025 & 2035 (%)
  • 6.6 CD22
    • 6.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 6.6.2 Market Share by Region, 2025 & 2035 (%)
  • 6.7 CD33
    • 6.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 6.7.2 Market Share by Region, 2025 & 2035 (%)
  • 6.8 Other Target Antigens
    • 6.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 6.8.2 Market Share by Region, 2025 & 2035 (%)

7 Antibody Drug Conjugates Market Analysis by Applications

  • 7.1 Key Findings
  • 7.2 Applications Segment: Market Attractiveness Index
  • 7.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 7.4 Blood Cancer
    • 7.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 7.4.2 Market Share by Region, 2025 & 2035 (%)
  • 7.5 Breast Cancer
    • 7.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 7.5.2 Market Share by Region, 2025 & 2035 (%)
  • 7.6 Ovarian Cancer
    • 7.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 7.6.2 Market Share by Region, 2025 & 2035 (%)
  • 7.7 Lung Cancer
    • 7.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 7.7.2 Market Share by Region, 2025 & 2035 (%)
  • 7.8 Other Applications
    • 7.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
    • 7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Antibody Drug Conjugates Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Antibody Drug Conjugates Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Antibody Drug Conjugates Market Attractiveness Index
  • 9.3 North America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 9.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 9.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 9.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
  • 9.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 9.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 9.9 U.S. Antibody Drug Conjugates Market Analysis
  • 9.10 Canada Antibody Drug Conjugates Market Analysis

10 Europe Antibody Drug Conjugates Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Antibody Drug Conjugates Market Attractiveness Index
  • 10.3 Europe Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 10.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 10.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 10.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 10.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 10.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 10.9 Germany Antibody Drug Conjugates Market Analysis
  • 10.10 UK Antibody Drug Conjugates Market Analysis
  • 10.11 France Antibody Drug Conjugates Market Analysis
  • 10.12 Italy Antibody Drug Conjugates Market Analysis
  • 10.13 Spain Antibody Drug Conjugates Market Analysis
  • 10.14 Russia Antibody Drug Conjugates Market Analysis
  • 10.15 Rest of Europe Antibody Drug Conjugates Market Analysis

11 Asia Pacific Antibody Drug Conjugates Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
  • 11.3 Asia Pacific Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 11.4 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 11.6 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 11.7 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 11.8 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 11.9 Japan Antibody Drug Conjugates Market Analysis
  • 11.10 China Antibody Drug Conjugates Market Analysis
  • 11.11 India Antibody Drug Conjugates Market Analysis
  • 11.12 Australia Antibody Drug Conjugates Market Analysis
  • 11.13 South Korea Antibody Drug Conjugates Market Analysis
  • 11.14 South-East Asia Antibody Drug Conjugates Market Analysis
  • 11.15 Rest of Asia Pacific Antibody Drug Conjugates Market Analysis

12 Latin America Antibody Drug Conjugates Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Antibody Drug Conjugates Market Attractiveness Index
  • 12.3 Latin America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 12.4 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 12.5 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 12.6 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 12.7 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 12.8 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 12.9 Brazil Antibody Drug Conjugates Market Analysis
  • 12.10 Mexico Antibody Drug Conjugates Market Analysis
  • 12.11 Argentina Antibody Drug Conjugates Market Analysis
  • 12.12 Colombia Antibody Drug Conjugates Market Analysis
  • 12.13 Rest of Latin America Antibody Drug Conjugates Market Analysis

13 MEA Antibody Drug Conjugates Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Antibody Drug Conjugates Market Attractiveness Index
  • 13.3 MEA Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 13.4 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Country
  • 13.5 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
  • 13.6 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
  • 13.7 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
  • 13.8 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
  • 13.9 GCC Antibody Drug Conjugates Market Analysis
  • 13.10 South Africa Antibody Drug Conjugates Market Analysis
  • 13.11 Rest of MEA Antibody Drug Conjugates Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape
    • 14.1.1 Strategic Collaborations in the ADC Space to Redefine Cancer Treatment
    • 14.1.2 Pioneering Innovations Redefining Cancer Care and Broader Health Solutions
  • 14.2 Takeda Pharmaceutical Company Limited
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2018-2023
      • 14.2.3.2 R&D, 2018-2023
      • 14.2.3.3 Regional Market Shares, 2023
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 F. Hoffmann-La Roche Ltd.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2018-2023
      • 14.3.3.2 R&D, 2018-2023
      • 14.3.3.3 Business Segment Market Shares, 2023
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Pfizer Inc.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2018-2023
      • 14.4.3.2 R&D, 2018-2023
      • 14.4.3.3 Regional Market Shares, 2023
      • 14.4.3.4 Business Segment Market Shares, 2023
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 AstraZeneca
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2018-2023
      • 14.5.3.2 R&D, 2018-2023
      • 14.5.3.3 Regional Market Shares, 2023
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Gilead Sciences, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2018-2023
      • 14.6.3.2 R&D, 2018-2023
      • 14.6.3.3 Regional Market Shares, 2023
      • 14.6.3.4 Business Segment Market Shares, 2023
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Astellas Pharma Inc.
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2018-2023
      • 14.7.3.2 R&D, 2018-2023
      • 14.7.3.3 Regional Market Shares, 2023
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Daiichi Sankyo Company, Limited
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 GSK plc
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2018-2023
      • 14.9.3.2 R&D, 2018-2023
      • 14.9.3.3 Regional Market Shares, 2023
      • 14.9.3.4 Business Segment Market Shares, 2023
    • 14.9.4 Product Benchmarking
  • 14.10 ADC Therapeutics SA
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2018-2023
      • 14.10.3.2 R&D, 2018-2023
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Synaffix BV (now a part of Lonza)
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Strategic Outlook
  • 14.12 Byondis
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Product Benchmarking
  • 14.13 AbbVie Inc.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2018-2023
      • 14.13.3.2 R&D, 2018-2023
      • 14.13.3.3 Regional Market Shares, 2023
      • 14.13.3.4 Business Segment Market Shares, 2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 RemeGen
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Oxford BioTherapeutics
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Product Benchmarking
  • 14.16 Mersana Therapeutics
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Product Benchmarking
  • 14.17 WuXi AppTec
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2018-2023
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Genmab A/S
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2018-2023
      • 14.18.3.2 R&D, 2018-2023
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Regeneron Pharmaceuticals Inc.
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2018-2023
      • 14.19.3.2 R&D, 2018-2023
      • 14.19.3.3 Regional Market Shares, 2023
      • 14.19.3.4 Business Segment Market Shares, 2023
    • 14.19.4 Product Benchmarking

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Antibody Drug Conjugates Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
  • Table 2 Antibody Drug Conjugates Drugs Market: Pipeline
  • Table 3 Snapshot of Few Antibody Drug Conjugates Investment Deals
  • Table 4 Antibody Drug Conjugates Drugs Market: Approved ADCs
  • Table 5 Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 6 MMAE Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 7 DM4 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 8 Camptothecin Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 9 DM1 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 10 MMAF Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 11 Other Payload Type Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 12 Antibody Drug Conjugates Market Forecast by Technology, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 13 Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 14 Non-Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 15 Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 16 CD30 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 17 HER2 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 18 CD22 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 19 CD33 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 20 Other Target Antigens Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 21 Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 22 Blood Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 23 Breast Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 24 Ovarian Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 25 Lung Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 26 Other Applications Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
  • Table 27 Antibody Drug Conjugates Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 28 North America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 29 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 30 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 31 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 32 North America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 33 U.S. Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 34 Canada Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 35 Europe Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 36 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 37 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 38 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 39 Europe Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 40 Germany Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 41 UK Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 42 France Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 43 Italy Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 44 Spain Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 45 Russia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 46 Rest of Europe Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 47 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 48 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 49 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 50 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 51 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 52 Japan Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 53 China Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 54 India Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 55 Australia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 56 South Korea Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 57 South-East Asia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 58 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 59 Latin America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 60 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 61 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 62 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 63 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 64 Brazil Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 65 Mexico Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 66 Argentina Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 67 Colombia Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 68 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 69 MEA Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 70 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 71 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 72 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 73 MEA Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 74 GCC Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 75 South Africa Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 76 Rest of MEA Antibody Drug Conjugates Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 77 Antibody Drug Conjugates Market, Ranking 2024
  • Table 78 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 80 Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 81 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 83 F. Hoffmann-La Roche Ltd.: Strategic Outlook
  • Table 84 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Pfizer Inc.: Product & Services Benchmarking
  • Table 86 Pfizer Inc.: Strategic Outlook
  • Table 87 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 AstraZeneca: Product Benchmarking
  • Table 89 AstraZeneca: Strategic Outlook
  • Table 90 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Gilead Sciences, Inc.: Product Benchmarking
  • Table 92 Gilead Sciences, Inc.: Strategic Outlook
  • Table 93 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Astellas Pharma Inc.: Product Benchmarking
  • Table 95 Astellas Pharma Inc.: Strategic Outlook
  • Table 96 Daiichi Sankyo Company, Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Daiichi Sankyo Company, Limited: Product Benchmarking
  • Table 98 Daiichi Sankyo Company, Limited: Strategic Outlook
  • Table 99 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 GSK plc: Product Benchmarking
  • Table 101 ADC Therapeutics SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 ADC Therapeutics SA: Product Benchmarking
  • Table 103 ADC Therapeutics SA: Strategic Outlook
  • Table 104 Synaffix BV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Synaffix BV: Product Benchmarking
  • Table 106 Synaffix BV: Strategic Outlook
  • Table 107 Byondis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Byondis: Product Benchmarking
  • Table 109 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 AbbVie Inc.: Product Benchmarking
  • Table 111 AbbVie Inc.: Strategic Outlook
  • Table 112 RemeGen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 RemeGen: Product Benchmarking
  • Table 114 RemeGen: Strategic Outlook
  • Table 115 Oxford BioTherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Oxford BioTherapeutics: Product Benchmarking
  • Table 117 Mersana Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Mersana Therapeutics: Product Benchmarking
  • Table 119 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 WuXi AppTec: Product Benchmarking
  • Table 121 WuXi AppTec: Strategic Outlook
  • Table 122 Genmab A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 123 Genmab A/S: Product Benchmarking
  • Table 124 Genmab A/S: Strategic Outlook
  • Table 125 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Regeneron Pharmaceuticals Inc.: Product Benchmarking

List of Figures

  • Figure 1 Antibody Drug Conjugates Market Segmentation
  • Figure 2 Antibody Drug Conjugates Market by Payload Type: Market Attractiveness Index
  • Figure 3 Antibody Drug Conjugates Market by Linker Type: Market Attractiveness Index
  • Figure 4 Antibody Drug Conjugates Market by Target Antigen: Market Attractiveness Index
  • Figure 5 Antibody Drug Conjugates Market by Applications: Market Attractiveness Index
  • Figure 6 Antibody Drug Conjugates Market Attractiveness Index by Region
  • Figure 7 Antibody Drug Conjugates Market: Market Dynamics
  • Figure 8 Antibody Drug Conjugates Market: Impact Analysis
  • Figure 9 Antibody Drug Conjugates Market: Generalized Process Flow for ADCs
  • Figure 10 Antibody Drug Conjugates Market: SWOT Analysis
  • Figure 11 Antibody Drug Conjugates Market: Porter's Five Forces Analysis
  • Figure 12 Antibody Drug Conjugates Market: PEST Analysis
  • Figure 13 Antibody Drug Conjugates Deals, 2010-2023
  • Figure 14 Antibody Drug Conjugates Market Attractiveness Index by Payload Type
  • Figure 15 Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 16 Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025, 2030, 2035 (%)
  • Figure 17 MMAE Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 18 MMAE Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 19 DM4 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 20 DM4 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 21 Camptothecin Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 22 Camptothecin Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 23 DM1 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 24 DM1 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 25 MMAF Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 26 MMAF Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 27 Other Payload Type Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 28 Other Payload Type Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 29 Antibody Drug Conjugates Market Attractiveness Index by Linker Type
  • Figure 30 Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 31 Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025, 2030, 2035 (%)
  • Figure 32 Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 33 Cleavable Linkers Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 34 Non-Cleavable Linkers Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 35 Non-Cleavable Linkers Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 36 Antibody Drug Conjugates Market Attractiveness Index by Target Antigen
  • Figure 37 Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
  • Figure 38 Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025, 2030, 2035 (%)
  • Figure 39 CD30 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 40 CD30 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 41 HER2 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 42 HER2 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 43 CD22 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 44 CD22 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 45 CD33 Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 46 CD33 Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 47 Other Target Antigens Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 48 Other Target Antigens Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 49 Antibody Drug Conjugates Market Attractiveness Index by Applications
  • Figure 50 Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 51 Antibody Drug Conjugates Market Share Forecast by Applications, 2025, 2030, 2035 (%)
  • Figure 52 Blood Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 53 Blood Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 54 Breast Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 55 Breast Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 56 Ovarian Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 57 Ovarian Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 58 Lung Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 59 Lung Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 60 Other Applications Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 61 Other Applications Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 62 Antibody Drug Conjugates Market Forecast by Region 2025, 2030, 2035 (Revenue, CAGR%)
  • Figure 63 Antibody Drug Conjugates Market Share Forecast by Region 2025, 2030, 2035 (%)
  • Figure 64 Antibody Drug Conjugates Market by Region, 2025-2035 (US$ Billion)
  • Figure 65 North America Antibody Drug Conjugates Market Attractiveness Index
  • Figure 66 North America Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 67 North America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 68 North America Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 69 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 70 North America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
  • Figure 71 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 72 North America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 73 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
  • Figure 74 North America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
  • Figure 75 North America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 76 North America Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
  • Figure 77 U.S. Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 78 Canada Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 79 Europe Antibody Drug Conjugates Market Attractiveness Index
  • Figure 80 Europe Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 81 Europe Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 82 Europe Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 83 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 84 Europe Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
  • Figure 85 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 86 Europe Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 87 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
  • Figure 88 Europe Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
  • Figure 89 Europe Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 90 Europe Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
  • Figure 91 Germany Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 92 UK Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 93 France Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 94 Italy Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 95 Spain Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 96 Russia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 97 Rest of Europe Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 98 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
  • Figure 99 Asia Pacific Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 100 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 101 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 102 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 103 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
  • Figure 104 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 105 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 106 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 107 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 108 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 109 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
  • Figure 110 Japan Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 111 China Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 112 India Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 113 Australia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 114 South Korea Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 115 South-East Asia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 116 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 117 Latin America Antibody Drug Conjugates Market Attractiveness Index
  • Figure 118 Latin America Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 119 Latin America Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 120 Latin America Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 121 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 122 Latin America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
  • Figure 123 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 124 Latin America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 125 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
  • Figure 126 Latin America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
  • Figure 127 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 128 Latin America Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
  • Figure 129 Brazil Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 130 Mexico Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 131 Argentina Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 132 Colombia Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 133 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 134 MEA Antibody Drug Conjugates Market Attractiveness Index
  • Figure 135 MEA Antibody Drug Conjugates Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 136 MEA Antibody Drug Conjugates Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 137 MEA Antibody Drug Conjugates Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 138 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 139 MEA Antibody Drug Conjugates Market Share Forecast by Payload Type, 2025 & 2035 (%)
  • Figure 140 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 141 MEA Antibody Drug Conjugates Market Share Forecast by Linker Type, 2025 & 2035 (%)
  • Figure 142 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2025-2035 (US$ Billion, AGR %)
  • Figure 143 MEA Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2025 & 2035 (%)
  • Figure 144 MEA Antibody Drug Conjugates Market Forecast by Applications, 2025-2035 (US$ Billion, AGR %)
  • Figure 145 MEA Antibody Drug Conjugates Market Share Forecast by Applications, 2025 & 2035 (%)
  • Figure 146 GCC Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 147 South Africa Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 148 Rest of MEA Antibody Drug Conjugates Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 149 Takeda Pharmaceutical Company Limited: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 150 Takeda Pharmaceutical Company Limited: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 151 Takeda Pharmaceutical Company Limited: Regional Market Shares (%), 2023
  • Figure 152 F. Hoffmann-La Roche Ltd.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 153 F. Hoffmann-La Roche Ltd.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 154 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares (%), 2023
  • Figure 155 Pfizer Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 156 Pfizer Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 157 Pfizer Inc.: Regional Market Shares (%), 2023
  • Figure 158 Pfizer Inc.: Business Segment Market Shares (%), 2023
  • Figure 159 AstraZeneca: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 160 AstraZeneca: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 161 AstraZeneca: Regional Market Shares (%), 2023
  • Figure 162 Gilead Sciences, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 163 Gilead Sciences, Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 164 Gilead Sciences, Inc.: Regional Market Shares (%), 2023
  • Figure 165 Gilead Sciences, Inc.: Business Segment Market Shares (%), 2023
  • Figure 166 Astellas Pharma Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 167 Astellas Pharma Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 168 Astellas Pharma Inc.: Regional Market Shares (%), 2023
  • Figure 169 GSK plc: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 170 GSK plc: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 171 GSK plc: Regional Market Shares (%), 2023
  • Figure 172 GSK plc: Business Segment Market Shares (%), 2023
  • Figure 173 ADC Therapeutics SA: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 174 ADC Therapeutics SA: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 175 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 176 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 177 AbbVie Inc.: Regional Market Shares (%), 2023
  • Figure 178 AbbVie Inc.: Business Segment Market Shares (%), 2023
  • Figure 179 WuXi AppTec: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 180 Genmab A/S: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 181 Genmab A/S: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 182 Regeneron Pharmaceuticals Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 183 Regeneron Pharmaceuticals Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 184 Regeneron Pharmaceuticals Inc.: Regional Market Shares (%), 2023
  • Figure 185 Regeneron Pharmaceuticals Inc.: Business Segment Market Shares (%), 2023